Soluble klotho as a marker of renal fibrosis and podocyte injuries in human kidneys

Nam-Jun Cho1*, Dong-Jae Han1#, Ji-Hye Lee2, Si-Hyong Jang2, Jeong Suk Kang1, Hyo-Wook Gil1, Samel Park1, Eun Young Lee1*

1 Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea,
2 Department of Pathology, Soonchunhyang University Cheonan Hospital, Cheonan, Korea

* These authors contributed equally to this work.

Abstract

Klotho deficiency is relevant to renal fibrosis and podocyte injury in vivo and in vitro. We investigated whether histological findings of renal biopsy specimens were associated with the levels of soluble klotho in humans. We investigated renal biopsy specimens of 67 patients and detailed microscopic findings were reviewed. Soluble serum/urinary klotho and urinary angiotensinogen were assessed by enzyme-linked immunosorbent assays, and tissue klotho expression was assessed by immunohistochemical staining. The median age of the study participants was 35.6 years. High serum klotho levels (\(\geq 14\) pg/mL) were associated with decreased odds ratios (ORs) of interstitial fibrosis (OR = 0.019, \(P = 0.003\)) and segmental sclerosis (OR = 0.190, \(P = 0.022\)) in multivariable logistic regression analysis. Patients with a lower urinary klotho-to-creatinine ratio (UKCR) were significantly more likely to have diffuse foot process effacement (OR = 0.450, \(P = 0.010\)). The area under the receiver-operating characteristic curve (AUC) of serum klotho for predicting interstitial fibrosis was 0.920 (95% CI, 0.844–0.996), and the best cut-off value of serum klotho was 138.1 pg/mL. The AUC of UKCR for predicting diffuse foot process effacement was 0.754 (95% CI, 0.636–0.872), and the best cut-off value of UKCR was 96.7 pg/mgCr. Urinary angiotensinogen-to-creatinine ratio was not associated with serum klotho, UKCR, or any pathological finding. Our data suggested that soluble serum and urinary klotho levels represent a potential biomarker to predict renal fibrosis and podocyte injury in humans.

Introduction

The klotho gene was first identified as an anti-aging gene in 1997 [1]. Klotho is a type I single-pass transmembrane protein expressed in various organs, and is especially abundant in the kidney [2]. Membranous klotho has an important role in phosphate metabolism by acting as a co-receptor with fibroblast growth factor (FGF) receptors for the FGF23 ligand [3]. Klotho is released as a soluble and secreted form by alternative splicing of the klotho gene or by cleavage of large extracellular domain of transmembrane klotho [4, 5]. Soluble klotho acts as a hormonal factor to inhibit cellular apoptosis, anti-oxidation, inhibition of fibrosis, and modulation of ion transport [6–9].
Soluble klotho is present in blood, urine and cerebrospinal fluid, and is quantified by enzyme-linked immunosorbent assays [10, 11]. Reduced serum and urinary klotho levels are observed in the early stages of acute kidney injury and chronic kidney disease (CKD), with progressive decline in more advanced stages [12–14]. Progression of renal diseases is commonly associated with renal fibrosis, which is histologically evident as interstitial fibrosis/tubular atrophy (IFTA) and glomerulosclerosis [15, 16]. Several animal models reported that klotho deficiency triggers renal fibrosis via inhibition of growth factors, enhanced endoplasmic reticulum stress, up-regulation of transient receptor potential channels, and up-regulation of the renin-angiotensin system (RAS) [17–20]. However, no human studies have examined the association between soluble klotho and renal fibrosis, and the exact role of soluble klotho in renal fibrosis in humans is unknown.

Reduced blood klotho concentration is also associated with increased albuminuria, especially in patients with diabetes [21, 22]. Although klotho is mainly expressed in renal tubules, and more abundantly in the distal convoluted tubules, a recent study reported that the glomerulus is another source of klotho expression [23]. In the same study, administration of recombinant klotho protected against slit diaphragm disruption induced by the overexpression of TRPC6 in mice. In addition to renal fibrosis, it is unclear whether podocyte foot process changes are correlated with soluble klotho level.

In the present study, we tested the hypothesis that histological findings of renal biopsy specimens are associated with serum/urine soluble klotho levels. Urinary angiotensinogen levels were also evaluated to explore the role of RAS with soluble klotho in renal fibrosis. We report that serum and urinary klotho levels are strongly correlated with renal fibrosis and foot process effacement of podocyte, respectively. The results support the translation of in vivo and in vitro data to clinical settings.

Materials and methods

Study population and study design

Between July 2009 and August 2011, 70 patients who underwent renal biopsy at the Soonchunhyang University Cheonan Hospital (Cheonan, Republic of Korea) were enrolled. Three patients including two who had inadequate biopsy specimens and one who was diagnosed with renal cell carcinoma, were excluded. A renal biopsy specimen was considered adequate if it contained ≥4 glomeruli. The study was conducted in accordance with the 1975 Declaration of Helsinki and with the 2000 revision, and was approved by the Institutional Review Board (IRB) of the Soonchunhyang University Cheonan Hospital. The need for informed consent was waived by the IRB, as the current study was considered a retrospective review of anonymized clinical data.

Clinical and laboratory information

Baseline clinical characteristics determined the day before renal biopsy included age, gender, weight, height, body mass index (BMI), diabetes mellitus (DM), hypertension (HTN), urinary protein-to-creatinine ratio (UPCR), blood urea nitrogen, serum creatinine, estimated glomerular filtration rate (eGFR), serum calcium, serum phosphorus, serum albumin, total cholesterol, and triglyceride (TG) level. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [24].

Pathology

All renal biopsy specimens (n = 67) were reviewed and confirmed by two independent pathologists (JH Lee, SH Jang). Biopsy specimens were prepared according to standard protocols for
light microscopy, immunofluorescence, and electron microscopy (for details, see S1 Appendix). The percentage of glomeruli affected by segmental or global glomerulosclerosis was assessed by dividing the number of sclerosing glomeruli with the total number of acquired glomeruli. The degree of foot process effacement was assessed based on the percentage of evaluated areas and grouped as follows: absent, 0–10%; focal mild, 10–30%; focal moderate, 30–50%; focal severe, 50–70%; and diffuse, ≥70%. IFTA was evaluated semi-quantitatively according to the proportion of the cortical area involved, and grouped as follows: absent, <1%; mild, 1–25%; moderate, 25–50%; and severe, ≥50% of the total area. Intimal thickening was assessed as the percentage of narrowing lumen of the most severely affected blood vessel, and classified as follows: absent, 0%; mild, <25%; moderate, 25–50%; and severe, ≥50%.

The expression of klotho in renal biopsy specimens was evaluated using immunohistochemistry (IHC). Tissue sections (2-μm thickness) were cut, deparaffinized in xylene, and hydrated using an ethanol-deionized water series. Endogenous peroxidase activity was blocked using 3% H₂O₂ in methanol for 15 min. Sections were washed and stained with a 1:200 dilution of rabbit polyclonal antibody against klotho (LS-B6625; LifeSpan BioSciences, Seattle, WA, USA). Primary antibody binding was detected using Bond Polymer Refine Detection Kit (Leica, Wetzlar, Germany). Slides were counterstained with hematoxylin.

Renal klotho expression was semi-quantitatively calculated using H-score method which is commonly used for IHC evaluation [25]. Briefly, predominant cytoplasmic staining intensities were designated as negative (0), weak (1+), or strong (2+) and the percentage of distal tubule cells at each staining intensity level was calculated. Finally, an H-score was assigned using the following formula: 2 × percentage of strongly staining cells + 1 × percentage of weakly staining cells, giving a possible range of 0–200. All cases with discrepancy in IHC scoring were reanalyzed and discussed between both pathologists.

**ELISA of soluble klotho and urinary angiotensinogen**

Blood samples were centrifuged for 15 min at 3,000 rpm within 30 min of collection. The serum was extracted and stored at -70°C until analysis. Urine samples were centrifuged for 10 min at 3,000 rpm to remove particulate matter and stored at -70°C until analysis. Serum and urinary concentrations of klotho were analyzed by Human Soluble alpha-klotho Assay Kits (Immuno-Biological Laboratories, Gunma, Japan) and urinary angiotensinogen concentrations were measured with a Human Total Angiotensinogen Assay Kit (Immuno-Biological Laboratories, Gunma, Japan) according to the manufacturer’s instructions. All samples were analyzed twice and the intra- and inter-assay coefficients of variation were <10%. The levels of urinary klotho or angiotensinogen were expressed as the ratio of urinary klotho or angiotensinogen-to-urinary creatinine to assess the patients’ hydration and renal function.

**Statistical analysis**

Statistical analyses were performed using R version 3.4.0 (The R Foundation for Statistical Computing, Vienna, Austria). Serum klotho, urinary klotho, and urinary angiotensinogen values were missing in 13, 2, and 9 patients respectively. Thus, each analysis was performed after excluding participants with missing values. Categorical variables were expressed as counts (percentage), normally distributed continuous variables as means ± SD, and non-normally distributed continuous variables as medians (interquartile ranges). Significantly skewed variables were logarithmically transformed where possible. Differences between groups were analyzed by Mann-Whitney U test or Kruskal-Wallis tests according to the number of groups. Pearson’s correlation coefficient or Spearman’s rank correlation coefficient was used to test
the correlation between individual continuous variables. In multiple comparisons, pairwise Mann-Whitney U test with Bonferroni correction was performed between the groups. Categorical variables were analyzed using the Pearson’s Chi-squared test or Fisher’s exact test as appropriate. Multivariable logistic regression was performed to identify the association between soluble klotho and pathologic features after adjustment for possible confounders. To measure the sensitivity and specificity of serum/urinary klotho at different cut-off values, a conventional ROC curve was generated. Best cut-off values were determined by selecting the data point that maximized the sum of sensitivity and specificity. P-value < 0.05 was regarded as statistically significant and two-tailed tests were performed in all hypothesis tests.

**Results**

**Baseline characteristics**

The median age of 67 study participants was 35.6 (19.9–48.5) years. Nineteen (27.5%) patients had HTN and 3 (4.3%) patients had DM. The median values of eGFR and UPCR were 109.4 (79.8–130.3) mL/min/1.73 m² and 545.4 (range, 193.5–2032.0) mg/gCr. The median serum klotho level was 14.0 (7.0–122.2) pg/mL, the median urinary klotho-to-creatinine ratio (UKCR) was 76.6 (range, 12.1–197.2) pg/mgCr, and the median urinary angiotensinogen-to-creatinine ratio (UAngCR) was 17.1 (8.4–27.3) ng/mgCr.

**Renal biopsy findings**

In the renal biopsy specimens of these patients, immunoglobulin A (IgA) nephropathy was diagnosed in 26 (38.8%) patients, focal segmental glomerulosclerosis in 12 (17.9%) patients, minimal change disease in 7 (10.4%) patients, membranous nephropathy and thin basement membrane disease in 3 (4.5%) patients, membranous proliferative glomerulonephritis in 2 (3.0%) patients, and post-infectious glomerulonephritis, lupus nephritis, crescentic glomerulonephritis, acute tubular necrosis, amyloidosis were diagnosed in 1 (1.5%) patient each. The specimens of 9 (13.4%) patients showed nonspecific findings. There was no significant correlation between soluble klotho level and pathological diagnosis.

Detailed microscopic findings are presented in Table 1.

**Association of pathological findings with serum klotho levels**

Serum klotho levels varied with the degree of segmental glomerulosclerosis ($P = 0.003$), tubular atrophy ($P < 0.001$), interstitial fibrosis ($P < 0.001$), and arterial intimal thickening ($P = 0.02$). Serum klotho levels in the absence of interstitial fibrosis (208.5 [148.9–433.2] pg/mL) were significantly higher than in mild (7.5 [6.1–43.5] pg/mL) and moderate interstitial fibrosis (10.9 [7.3–43.0] pg/mL). Serum klotho levels in the absence of segmental glomerulosclerosis (95.5 [12.9–216.4] pg/mL) were significantly higher than in moderate segmental glomerulosclerosis (6.4 [5.3–7.1] pg/mL) (Fig 1).

Patients were divided into binary groups according to their serum klotho levels. The cut-off point was selected based on the median value (14 pg/mL). Baseline demographics and clinical characteristics of the two groups are presented in Table 2. No significant differences in parameters were detected between the two groups. Multivariable logistic regression was performed adjusting for other variables that potentially affect outcomes. If serum klotho level was high ($\geq 14$ pg/mL), the odds ratios (ORs) of interstitial fibrosis (OR = 0.019, $P = 0.003$) and segmental sclerosis (OR = 0.190, $P = 0.022$) were decreased after adjustment for age, gender, BMI, DM, HTN, eGFR, and log UPCR (Table 3). Representative light microscopic images of patients in the high and low serum klotho groups are presented in Fig 2.
Association of pathological findings with urinary klotho levels

Baseline demographics and clinical characteristics of 65 patients and relationship with urinary klotho are presented in Table 4. Log-transformed UKCR was used because of normal distribution after the transformation. Baseline eGFR levels were significantly associated with urinary klotho levels ($R = 0.273$, $P = 0.028$) and DM participants had lower log UKCR levels ($1.8 \pm 0.4$) compared with non-DM participants ($4.3 \pm 1.6$, $P = 0.02$) (Table 4). The log UKCR levels differed according to the degree of global glomerulosclerosis ($P = 0.033$) and foot process effacement of podocyte ($P = 0.009$). The log UKCR levels among the groups of global glomerulosclerosis did not show a consistent trend; patients who had $\geq 70\%$ of foot process effacement ($3.3 \pm 1.3$ pg/mgCr) revealed less log UKCR levels than patients who had $<30\%$ of foot process effacement ($4.5 \pm 1.8$ pg/mgCr) and $30-70\%$ of foot process effacement ($4.8 \pm 1.6$ pg/mgCr) (Fig 3).

Multivariable logistic regression was performed to assess the relationship between urinary klotho levels and the degree of foot process effacement after adjusting for other variables. After adjustment for age, gender, BMI, DM, HTN, eGFR, and interstitial fibrosis, the OR of diffuse foot process effacement was decreased as each pg/mgCr of log UKCR was increased (OR =

| Microscopic findings | Grade | Number (%) |
|----------------------|-------|------------|
| **Glomerular changes** |       |            |
| Globally sclerosed glomeruli | Absent | 30 (44.8) |
| | $<25\%$ | 24 (35.8) |
| | $25-50\%$ | 7 (10.5) |
| | $\geq 50\%$ | 6 (9.0) |
| Segmentally sclerosed glomeruli | Absent | 29 (43.3) |
| | $<25\%$ | 19 (28.4) |
| | $25-50\%$ | 11 (16.4) |
| | $\geq 50\%$ | 8 (11.9) |
| Podocyte foot process effacement | Absent | 6 (9.0) |
| | Focal mild | 14 (20.9) |
| | Focal moderate | 8 (11.9) |
| | Focal marked | 13 (19.4) |
| | Diffuse | 26 (38.8) |
| **Tubulointerstitial changes** |       |            |
| Tubular atrophy | Absent | 18 (26.9) |
| | Mild | 40 (59.7) |
| | Moderate | 6 (9.0) |
| | Severe | 3 (4.5) |
| Interstitial fibrosis | Absent | 18 (26.9) |
| | Mild | 40 (59.7) |
| | Moderate | 7 (10.5) |
| | Severe | 2 (3.0) |
| **Vascular changes** |       |            |
| Intimal thickening | Absent | 30 (44.8) |
| | Mild | 33 (49.3) |
| | Moderate | 2 (3.0) |
| | Severe | 2 (3.0) |

Mean number of glomeruli ($n = 67$) was $21.0 \pm 10.3$. The median percentage of globally sclerosed glomeruli was $4.9\%$ ($0-18.4\%$) and the median percentage of segmentally sclerosed glomeruli was $5.3\%$ ($0-33.3\%$).

https://doi.org/10.1371/journal.pone.0194617.t001

**Association of pathological findings with urinary klotho levels**

Baseline demographics and clinical characteristics of 65 patients and relationship with urinary klotho are presented in Table 4. Log-transformed UKCR was used because of normal distribution after the transformation. Baseline eGFR levels were significantly associated with urinary klotho levels ($R = 0.273$, $P = 0.028$) and DM participants had lower log UKCR levels ($1.8 \pm 0.4$) compared with non-DM participants ($4.3 \pm 1.6$, $P = 0.02$) (Table 4). The log UKCR levels differed according to the degree of global glomerulosclerosis ($P = 0.033$) and foot process effacement of podocyte ($P = 0.009$). The log UKCR levels among the groups of global glomerulosclerosis did not show a consistent trend; patients who had $\geq 70\%$ of foot process effacement ($3.3 \pm 1.3$ pg/mgCr) revealed less log UKCR levels than patients who had $<30\%$ of foot process effacement ($4.5 \pm 1.8$ pg/mgCr) and $30-70\%$ of foot process effacement ($4.8 \pm 1.6$ pg/mgCr) (Fig 3).

Multivariable logistic regression was performed to assess the relationship between urinary klotho levels and the degree of foot process effacement after adjusting for other variables. After adjustment for age, gender, BMI, DM, HTN, eGFR, and interstitial fibrosis, the OR of diffuse foot process effacement was decreased as each pg/mgCr of log UKCR was increased (OR =
Serum/urinary klotho as a biomarker predicting renal pathology

The AUC of serum klotho was 0.920 (95% CI, 0.844–0.996) for predicting interstitial fibrosis (Fig 5A), and 0.736 (95% CI, 0.592–0.880) for predicting segmental sclerosis (Fig 5B). The best cut-off value of serum klotho was 138.1 pg/mL (sensitivity, 0.950; specificity, 0.786), for predicting interstitial fibrosis. It was 10.5 pg/mL (sensitivity, 0.645; specificity, 0.826), for predicting segmental sclerosis. A cut-off value 138.1 pg/mL also yielded good sensitivity (sensitivity, 0.935; specificity, 0.478) for predicting segmental sclerosis.

Fig 1. Comparison of serum klotho levels in different groups for each pathology. Boxplots for serum klotho levels are presented according to the severity of each pathologic finding: (A) Interstitial fibrosis, (B) tubular atrophy, (C) segmental sclerosis of glomeruli, and (D) intimal thickening of arterial wall. *P < 0.01; **P < 0.001.

https://doi.org/10.1371/journal.pone.0194617.g001

0.450, P = 0.010) (Table 5). Representative transmission electron microscopy images of patients according to the level of urinary klotho-to-creatinine ratio are presented in Fig 4.

Serum/urinary klotho as a biomarker predicting renal pathology

The AUC of serum klotho was 0.920 (95% CI, 0.844–0.996) for predicting interstitial fibrosis (Fig 5A), and 0.736 (95% CI, 0.592–0.880) for predicting segmental sclerosis (Fig 5B). The best cut-off value of serum klotho was 138.1 pg/mL (sensitivity, 0.950; specificity, 0.786), for predicting interstitial fibrosis. It was 10.5 pg/mL (sensitivity, 0.645; specificity, 0.826), for predicting segmental sclerosis. A cut-off value 138.1 pg/mL also yielded good sensitivity (sensitivity, 0.935; specificity, 0.478) for predicting segmental sclerosis.

Fig 1. Comparison of serum klotho levels in different groups for each pathology. Boxplots for serum klotho levels are presented according to the severity of each pathologic finding: (A) Interstitial fibrosis, (B) tubular atrophy, (C) segmental sclerosis of glomeruli, and (D) intimal thickening of arterial wall. *P < 0.01; **P < 0.001.

https://doi.org/10.1371/journal.pone.0194617.g001

0.450, P = 0.010) (Table 5). Representative transmission electron microscopy images of patients according to the level of urinary klotho-to-creatinine ratio are presented in Fig 4.

Serum/urinary klotho as a biomarker predicting renal pathology

The AUC of serum klotho was 0.920 (95% CI, 0.844–0.996) for predicting interstitial fibrosis (Fig 5A), and 0.736 (95% CI, 0.592–0.880) for predicting segmental sclerosis (Fig 5B). The best cut-off value of serum klotho was 138.1 pg/mL (sensitivity, 0.950; specificity, 0.786), for predicting interstitial fibrosis. It was 10.5 pg/mL (sensitivity, 0.645; specificity, 0.826), for predicting segmental sclerosis. A cut-off value 138.1 pg/mL also yielded good sensitivity (sensitivity, 0.935; specificity, 0.478) for predicting segmental sclerosis.
The AUC of UKCR for predicting diffuse foot process effacement was 0.754 (95% CI, 0.636–0.872) (Fig 5C). The best cut-off value of UKCR for predicting diffuse foot process effacement was 96.7 pg/mgCr (sensitivity, 0.875; specificity, 0.634).

### Association of urinary angiotensinogen levels with serum/urinary klotho levels

There was no clear association of UAngCR with serum klotho (rho = -0.088, P = 0.563) and UKCR (rho = 0.535, P = 0.689). Further, no significant differences were detected in UAngCR levels with the pathological findings. Compared with baseline demographics and clinical characteristics, UAngCR was significantly correlated with the patient’s age (rho = 0.574, P < 0.001), serum albumin (rho = -0.405, P = 0.002), serum calcium (rho = -0.477, P < 0.001), serum total cholesterol (rho = 0.408, P = 0.002), serum TG (rho = 0.313, P = 0.017), eGFR

**Table 2. Baseline demographics and clinical characteristics according to serum klotho level.**

|                        | Low serum klotho (< 14 pg/ml, n = 27) | High serum klotho (≥ 14 pg/ml, n = 27) | P-value |
|------------------------|--------------------------------------|----------------------------------------|---------|
| Klotho range, pg/ml    | 5.2–13.9                             | 14.0–790.9                             | –       |
| Age, years             | 37.3 (28.9–54.8)                     | 34.7 (19.3–45.1)                      | 0.223   |
| Sex, male (%)          | 14 (51.9)                            | 16 (59.3)                              | 0.584†  |
| Hypertension, present (%) | 7 (25.9)                     | 6 (22.2)                               | 0.750†  |
| Diabetes, present (%)  | 1 (3.7)                              | 2 (7.4)                                | 1.000‡  |
| BMI                    | 23.4 ± 3.3                           | 24.2 ± 4.5                             | 0.450   |
| Albumin, g/dl          | 3.93 ± 0.90                          | 3.75 ± 1.04                            | 0.652   |
| Urea nitrogen, mg/dl   | 14.5 (11.6–20.6)                     | 12.4 (10.8–19.0)                       | 0.489   |
| Creatinine, mg/dl      | 0.9 (0.7–1.1)                        | 0.8 (0.7–0.9)                          | 0.524   |
| Calcium, mg/dl         | 8.69 ± 0.70                          | 8.54 ± 0.72                            | 0.457   |
| Phosphorus, mg/dl      | 3.86 ± 0.63                          | 3.93 ± 0.91                            | 0.756   |
| Total cholesterol, mg/dl | 207.0 (171.5–290.0)                | 220.0 (158.5–279.5)                    | 0.678   |
| Triglycerides, mg/dl   | 120.0 (99.0–176.5)                   | 144.0 (86.0–208.5)                     | 0.622   |
| eGFR, ml/min per 1.73 m² | 96.2 (77.6–124.5)              | 115.7 (81.0–130.3)                     | 0.272   |
| UPCR, mg/gCr           | 425.0 (216.4–1912.1)                 | 780.0 (213.4–2867.5)                   | 0.539   |

Data are presented as mean ± SD, median (interquartile range), or count (%) as appropriate. P-values are calculated by

†Pearson’s Chi-squared test or

‡Fisher’s exact test for categorical variables, and by Mann–Whitney U test for continuous variables. BMI, body mass index; eGFR, estimated glomerular filtration rate; UPCR, urine protein to creatinine ratio.

[https://doi.org/10.1371/journal.pone.0194617.t002](https://doi.org/10.1371/journal.pone.0194617.t002)

**Table 3. Association of serum klotho level with interstitial fibrosis and segmental sclerosis.**

|                          | Low serum klotho | Presence of interstitial fibrosis | High serum klotho | P-value | Presence of segmental sclerosis | High serum klotho | P-value |
|--------------------------|------------------|----------------------------------|------------------|---------|---------------------------------|------------------|---------|
| Model 1*                 | 1 (reference)    | 0.041 (0.002–0.240)              | 0.003            |         | 0.228 (0.072–0.738)             | 0.016            |         |
| Model 2†                 | 1 (reference)    | 0.035 (0.002–0.244)              | 0.004            |         | 0.228 (0.059–0.783)             | 0.023            |         |
| Model 3‡                 | 1 (reference)    | 0.019 (0.001–0.173)              | 0.003            |         | 0.190 (0.041–0.746)             | 0.022            |         |

Presented as odds ratio (95% confidence interval) attained by multivariable logistic regression. Serum klotho levels were categorized into low and high serum klotho group according to their median values (14 pg/mL).

*Model 1: not adjusted

†Model 2: adjusted for age, gender, and body mass index

‡Model 3: adjusted for Model 2 variables plus diabetes mellitus, hypertension, estimated glomerular filtration rate, and log urine protein-to-creatinine ratio

[https://doi.org/10.1371/journal.pone.0194617.t003](https://doi.org/10.1371/journal.pone.0194617.t003)
(rho = -0.355, P = 0.006), and UPCR (rho = 0.321, P = 0.014). The UAngCR levels varied with the degree of HTN (P = 0.036).

IHC staining for klotho protein

We assessed klotho expression in the kidneys of 29 patients using an anti-klotho antibody. Klotho was expressed abundantly in the distal tubules of all patients. Expression was evident in

Table 4. Baseline demographics and clinical characteristics based on urinary klotho-to-creatinine ratio.

|                     | Values (N = 65) | rho | P-value |
|---------------------|----------------|-----|---------|
| Log UKCR, pg/mgCr   | 4.15 ± 1.67    | 0   | 0.752   |
| Age, years          | 35.6 (19.9–48.5) | -0.051 | 0.685 |
| Sex, male           | 39 (50.2)      | -   | 0.056   |
| Hypertension, present | 18 (26.9) | -  | 0.799   |
| Diabetes, present   | 3 (4.5)        | -   | 0.020   |
| BMI                 | 23.6 ± 3.9     | 0.107 | 0.194 |
| Albumin, g/dl       | 3.88 ± 0.99    | -   | 0.286   |
| Urea nitrogen, mg/dl| 14.5 (11.2–19.6) | -0.155 | 0.217 |
| Creatinine, mg/dl   | 0.8 (0.7–1.0)  | -0.150 | 0.233 |
| Calcium, mg/dl      | 8.64 ± 0.68    | 0.090 | 0.475   |
| Phosphorus, mg/dl   | 3.86 ± 0.82    | 0.093 | 0.460   |
| Total cholesterol, mg/dl | 203 (155.5–273.5) | -0.127 | 0.312 |
| Triglycerides, mg/dl| 141.0 (98.5–192.5) | 0.002 | 0.986   |
| eGFR, ml/min per 1.73 m² | 109.4 (79.8–130.3) | 0.273 | 0.028   |
| UPCR, mg/gCr        | 545.4 (193.5–2032.0) | -0.232 | 0.063   |

Data are presented as mean ± SD, median (interquartile range), or count (%) as appropriate. Pearson correlation coefficient or Spearman’s rank correlation coefficients with P-values are presented for the continuous variables. *P-values of Mann–Whitney U test are presented for the categorical variables. UKCR: urinary klotho-to-creatinine ratio; BMI: body mass index; eGFR: estimated glomerular filtration rate; UPCR: urinary protein-to-creatinine ratio.

https://doi.org/10.1371/journal.pone.0194617.t004
the proximal tubules of 3 patients. The median IHC staining score for distal tubule was 160.0 (120.0–170.0). IHC staining score for distal tubule was decreased as either interstitial fibrosis or tubular atrophy progressed, but there was no statistical significance (Fig 6). A detailed review of each slide revealed distal tubules surrounded by inflamed or fibrotic interstitium displaying absent or weaker IHC staining compared with tubules surrounded by intact interstitium (Fig 7). The IHC staining score for distal tubule was not correlated with serum klotho level (rho = -0.044, P = 0.128) and urinary klotho-to-creatinine ratio (rho = -0.096, P = 0.627).

**Discussion**

The progression of renal diseases is characterized by renal fibrosis, which histologically presents as IFTA and glomerulosclerosis [15, 16]. The fibrotic process within the tubulointerstitium and glomeruli involves infiltration of inflammatory cells, activation of fibroblasts and

| Diffuse effacement of foot process | Log UKCR | Odds ratio | P-value |
|-----------------------------------|----------|------------|---------|
| Model 1\(^a\)                     |          | 0.558 (0.374–0.790) | 0.002   |
| Model 2\(^b\)                     |          | 0.460 (0.256–0.733) | 0.003   |
| Model 3\(^c\)                     |          | 0.450 (0.224–0.778) | 0.010   |

Presented as odds ratios (95% confidence interval) based on multivariable logistic regression. Foot process effacement of podocyte was grouped according to absent/focal effacement (effacement <70%) and diffuse effacement (effacement ≥70%). Log-transformed urinary klotho-to-creatinine ratio was treated as a continuous variable (pg/mgCr). UKCR: urinary klotho-to-creatinine ratio.

\(^a\)Model 1: not adjusted

\(^b\)Model 2: adjusted for age, gender, and body mass index

\(^c\)Model 3: adjusted for Model 2 variables plus diabetes mellitus, hypertension, estimated glomerular filtration rate, and interstitial fibrosis.

https://doi.org/10.1371/journal.pone.0194617.t005
myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].

The present study clearly showed that serum klotho level and klotho expression in kidney tissues were decreased in the mild form of tubulointerstitial fibrosis, and showed a consistently downward trend with progressive fibrosis. Serum klotho was also negatively correlated with myofibroblasts, and epithelial-mesenchymal transition [26]. Klotho, an anti-aging protein, is an emerging target of renal fibrosis progression. Klotho exhibits anti-fibrotic effects by inhibiting multiple growth factors including TGF-β1, Wnt/β-catenin and insulin-like growth factor-1 (IGF-1) [8, 17, 27]. Administration of secreted klotho or genetic manipulation induces klotho overexpression to ameliorate renal fibrosis [17, 28].
the degree of segmental sclerosis. Furthermore, serum klotho level showed good discriminative ability to predict interstitial fibrosis and segmental sclerosis. Due to the high sensitivity of serum klotho for predicting renal fibrosis, we anticipate the absence of renal fibrosis at elevated serum klotho levels (cut-off value, 138.1 pg/mL). One study has reported that a down-regulation of klotho in renal tissue and peripheral blood mononuclear cell assessed by klotho promoter methylation is associated with tubulointerstitial fibrosis [29]. This suggests that klotho has an anti-fibrotic role in human renal interstitium, consistent with our results.

Our previous study reported that klotho deficiency was also associated with albuminuria, particularly in patients with diabetes [21]. While klotho expression is mainly observed in renal tubular cells, glomerulus is considered another site of klotho expression, and klotho deficiency...
has been associated with disruption of glomerular filtration [23]. Our study showed that UKCR was negatively correlated with diffuse foot process effacement of podocyte and not with IFTA or glomerulosclerosis. The results suggest that UKCR may reflect podocyte injury status. At a level of 96.7 pg/mgCr, UKCR also yielded good discriminative ability to predict diffuse foot process effacement.

We also focused on the role of RAS in klotho-renal fibrosis axis, especially intrarenal RAS activity, which was assessed based on urinary angiotensinogen [30]. Other studies reported that angiotensin inhibited klotho expression and klotho inhibited RAS activation [20, 31]. Therefore, it is plausible that soluble klotho and urinary angiotensinogen are negatively correlated. However in the present study, urinary angiotensinogen was not correlated with serum and urinary klotho, as well as renal expression of klotho. Urinary angiotensinogen was also not adequately correlated with the degree of renal fibrosis and other pathological findings in our study, although other studies suggested that urinary angiotensinogen represented a potential marker of deterioration of kidney function [32].

The level of serum klotho (14.0 [7.0–122.2] pg/mL) in the present study was significantly lower than in a previous study (580.2 [450.0–714.8], \( P < 0.001 \)) [21]. On the other hand, the UKCR levels were 76.6 (12.1–197.2) pg/mL in the present study compared with 14.9 (39.2–286.7) pg/mL in the previous study (\( P = 0.803 \)) [21]. In another study of serum klotho levels in CKD patients, the mean serum klotho level was 519 ± 183 pg/mL [33]. We attributed the discrepancy to active renal pathology of the participants in the present study, which inhibited the klotho expression. It was reported that fibrosis per se also inhibits kidney klotho expression via TNF superfamily inflammatory cytokines, TGF-β1, or angiotensin II [8, 27, 31, 34].

There are a few limitations in this study. First, the present study was cross-sectional in design. As renal biopsy and measurement of soluble klotho were conducted only at baseline, we could not determine the causality between klotho deficiency and changes in renal pathology. Monitoring the dynamic changes in biopsy findings and soluble klotho levels after appropriate treatment is essential to understand the mechanisms involved. Second, IHC staining for the detection of klotho protein was based only on a small number of patients. A certain trend between tissue klotho expression and pathologic findings was evident, but there was no statistical significance. Finally, the participants were limited to patients with glomerulonephritis and the findings may not be generalized to other renal conditions such as diabetic nephropathy, transplanted kidney, or other forms of CKD.

In conclusion, IFTA and segmental glomerulosclerosis in the biopsy specimens of human kidneys were associated with decreased serum klotho, and foot process effacement of podocyte was associated with decreased urinary klotho. Serum and urinary klotho showed favorable discriminative ability for predicting renal fibrosis and diffuse foot process effacement, respectively. The results highlight the potential of soluble klotho as a biomarker of renal fibrosis and podocyte injury in humans. The measurement of serum/urinary klotho ratio facilitates the sequential evaluation of renal disease progression in patients who are not available for renal biopsy.

**Supporting information**

S1 Appendix. Protocols for light microscopy, immunofluorescence, and electron microscopy.

(DOCX)

**Author Contributions**

**Conceptualization:** Dong-Jae Han, Eun Young Lee.
Formal analysis: Nam-Jun Cho, Samel Park.
Funding acquisition: Eun Young Lee.
Investigation: Ji-Hye Lee, Si-Hyong Jang, Jeong Suk Kang, Hyo-Wook Gil.
Methodology: Dong-Jae Han, Eun Young Lee.
Resources: Ji-Hye Lee, Eun Young Lee.
Supervision: Eun Young Lee.
Writing – original draft: Nam-Jun Cho.
Writing – review & editing: Nam-Jun Cho, Hyo-Wook Gil, Eun Young Lee.

References
1. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655):45–51. https://doi.org/10.1038/36285 PMID: 9363890
2. Ohyama Y, Kurabayashi M, Masuda H, Nakamura T, Aihara Y, Kaname T, et al. Molecular cloning of rat klotho cDNA: markedly decreased expression of klotho by acute inflammatory stress. Biochem Biophys Res Commun. 1998; 251(3):920–5. PMID: 9791011
3. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10):6120–3. https://doi.org/10.1074/jbc.C500457200 PMID: 16436388
4. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007; 104(50):19796–801. https://doi.org/10.1073/pnas.0709865104 PMID: 18056631
5. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun. 1998; 242(3):626–30. PMID: 9464267
6. Sugiyama H, Yoshida T, Mitobe M, Yoshida S, Shihoira S, Nitta K, et al. Klotho reduces apoptosis in experimental ischaemic acute kidney injury via HSP-70. Nephrol Dial Transplant. 2010; 25(1):60–8. https://doi.org/10.1093/ndt/gfp451 PMID: 19745103
7. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008; 389(3):233–41. https://doi.org/10.1515/BC.2008.028 PMID: 18177265
8. Sugiyama H, Yoshida T, Shihoira S, Kohei J, Mitobe M, Kurosu H, et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol. 2012; 302(10):F1252–64. https://doi.org/10.1152/ajprenal.00294.2011 PMID: 22338084
9. Cha SK, Hu MC, Kurosu H, Kuro-o M, Moe O, Huang CL. Regulation of renal outer medullary potassium channel and renal K⁺ excretion by Klotho. Mol Pharmacol. 2009; 76(1):38–46. https://doi.org/10.1124/mol.109.055780 PMID: 19349416
10. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22(1):124–56. https://doi.org/10.1681/ASN.2009121311 PMID: 21115613
11. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004; 565(1–3):143–7. https://doi.org/10.1016/j.febslet.2004.03.090 PMID: 15135068
12. Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012; 13:155. https://doi.org/10.1186/1471-2369-13-155 PMID: 23176706
13. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, et al. Circulating α-klotho levels in CKD and relationship to progression. Am J Kidney Dis. 2013; 61(6):899–909. https://doi.org/10.1053/j.ajkd.2013.01.024 PMID: 23540260
14. Hu MC, Moe OW. Klotho as a potential biomarker and therapy for acute kidney injury. Nat Rev Nephrol. 2012; 8(7):423–9. https://doi.org/10.1038/nmeph.2012.82 PMID: 22964799
15. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992; 20(1):1–17. PMID: 1621674
16. An Y, Xu F, Le W, Ge Y, Zhou M, Chen H, et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol Dial Transplant. 2015; 30(2):257–66. https://doi.org/10.1093/ndt/gfu250 PMID: 25063425

17. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011; 286(10):8655–65. https://doi.org/10.1074/jbc.M110.174037 PMID: 21209102

18. Liu QF, Ye JM, Deng ZY, Yu LX, Sun Q, Li SS. Ameliorating effect of Klotho on endoplasmic reticulum stress and renal fibrosis induced by unilateral ureteral obstruction. Iran J Kidney Dis. 2015; 9(4):291–7. PMID: 26174456

19. Wu YL, Xie J, An SW, Oliver N, Barrezueta NX, Lin MH, et al. Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho. Kidney Int. 2017; 91(4):830–41. https://doi.org/10.1016/j.kint.2016.09.039 PMID: 25084095

20. Zhou L, Mo H, Miao J, Zhou D, Tan RJ, Hou FF, et al. Klotho Ameliorates Kidney Injury and Fibrosis and Normalizes Blood Pressure by Targeting the Renin-Angiotensin System. Am J Pathol. 2015; 185(12):3211–23. https://doi.org/10.1016/j.ajpath.2015.08.004 PMID: 26475416

21. Lee EY, Kim SS, Lee JS, Kim IJ, Song SH, Cha SK, et al. Soluble α-Klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes. PLoS One. 2014; 9(8):e102984. https://doi.org/10.1371/journal.pone.0102984

22. Wu C, Wang Q, Lv C, Qin N, Lei S, Yuan Q, et al. The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin. Diabetes Res Clin Pract. 2014; 106(2):343–50. https://doi.org/10.1016/j.diabres.2014.08.026 PMID: 25263500

23. Kim JH, Xie J, Hwang KH, Wu YL, Oliver N, Eom M, et al. Klotho May Ameliorate Proteinuria by Targeting TRPC6 Channels in Podocytes. J Am Soc Nephrol. 2017; 28(1):140–51. https://doi.org/10.1681/ASN.2015080888 PMID: 27151926

24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604–12. PMID: 19414839

25. McCarty KS Jr., Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986; 46(8 Suppl):4244s–8s. PMID: 3524805

26. Carew RM, Wang B, Kantharidis P. The role of EMT in renal fibrosis. Cell Tissue Res. 2012; 347(1):103–16. https://doi.org/10.1007/s00441-011-1227-1 PMID: 21845400

27. Zhou L, Li Y, Zhou D, Tan RJ, Liu Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling. J Am Soc Nephrol. 2013; 24(5):771–85. https://doi.org/10.1681/ASN.2012080865 PMID: 23559584

28. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci U S A. 2007; 104(7):2331–6. https://doi.org/10.1073/pnas.061079104 PMID: 17287345

29. Chen J, Zhang X, Zhang H, Lin J, Zhang C, Wu Q, et al. Elevated Klotho Promoter Methylation Is Associated with Severity of Chronic Kidney Disease. PLOS ONE. 2013; 8(11):e79856. https://doi.org/10.1371/journal.pone.0079856

30. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensin as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007; 18(5):1558–65. https://doi.org/10.1681/ASN.2006060554 PMID: 17409316

31. Lim SC, Liu JJ, Subramaniam T, Sum CF. Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2014; 15(4):487–90. https://doi.org/10.1177/14703203143795095 PMID: 23380567

32. Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y, et al. Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007; 18(5):1558–65. https://doi.org/10.1681/ASN.2006060554 PMID: 17409316

33. Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, et al. Soluble α-Klotho Serum Levels in Chronic Kidney Disease. Int J Endocrinol. 2015; 2015:872193. https://doi.org/10.1155/2015/872193 PMID: 25873958

34. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, Jakubowski A, et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFκB. J Am Soc Nephrol. 2011; 22(7):1315–25. https://doi.org/10.1681/ASN.2010100173 PMID: 21719790